The Quantellect read.As of Nov 19, 2026, 9 active firms cover Sutro Biopharma: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $27.00 to $60.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $47.22 sits 454% above the current $8.52. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.74 next quarter toward $-6.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$47.22
+454.3% upside
Average target across 9 active firms as of Nov 19, 2026 vs $8.52 current
Highest Target$60.00
Average Target$47.22
Lowest Target$27.00
Detailed analyst forecasts for STRO
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate STRO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
STRO EPS & revenue forecast
EPS · NEXT QUARTER
$-1.74
Range $-1.74 – $-1.74 · 1 analysts · -41% YoY
Next period, 1 analysts expect Sutro Biopharma to earn $-1.74 a share (range $-1.74 – $-1.74), versus $-2.94 a year earlier. Full-year consensus is $-6.22, growing to $-6.07 the year after.
REVENUE · NEXT QUARTER
$7.1M
Range $2.0M – $10.0M · 1 analysts · -51% YoY
Revenue is expected to reach $7.1M (range $2.0M – $10.0M), -51.0% year-over-year. Full-year consensus is $44.5M, rising to $33.3M next year.
Top analysts covering Sutro Biopharma
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on STRO.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$60.00+604.2% to target
Overall win rate
48%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Neutral
$2.00-76.5% to target
Overall win rate
45%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$40.00+369.5% to target
Overall win rate
43%
+ Follow
#4
Andrew Berens
Leerink Partners · Rank #162
Buy
$43.00+404.7% to target
Overall win rate
53%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$50.00+486.9% to target
Overall win rate
39%
+ Follow
STRO stock forecast FAQ
What is STRO's average 12-month price target?+
The 9 active firms with a live target average $47.22 for Sutro Biopharma over the next 12 months, ranging from a $60.00 high to a $27.00 low, as of Nov 19, 2026.
Is STRO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for STRO?+
The Street-high target is $60.00 (Wedbush), and the Street-low is $27.00 (Wells Fargo). The average of all 9 active-firm targets is $47.22.
How many active Wall Street firms cover STRO?+
9 active firms have a recognized rating on Sutro Biopharma as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering STRO?+
Among analysts who currently cover STRO, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $60.00 target.
What is Sutro Biopharma's projected EPS for next quarter?+
The consensus estimate is $-1.74 per share (range $-1.74 – $-1.74) across 1 analysts. Full-year EPS is projected at $-6.22, rising to $-6.07 the following year.
How much revenue is Sutro Biopharma expected to report next quarter?+
Consensus revenue is $7.1M (range $2.0M – $10.0M). Full-year revenue is projected at $44.5M, growing to $33.3M next year.
Have analysts been upgrading or downgrading STRO lately?+
As of Nov 19, 2026, 9 of 9 active firms rate STRO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their STRO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.